News Presentations Publications

FILTERS

TOPICS

Positive Preclinical Findings from Inhaled NanoPac® Lung Study Published in the Journal of Aerosol Medicine and Pulmonary Drug Delivery

Preclinical Study Demonstrated Inhaled NanoPac Shows Prolonged Retention and Limited Systemic Exposure FORT WORTH/DALLAS, (October 30, 2018) — NanOlogy, a clinical-stage … Continued

More >

DFB Soria Completes a Phase 2 Clinical Trial of Submicron Particle Paclitaxel Anhydrous Ointment for Actinic Keratosis

Soria investigational drug provides evidence of actinic keratosis (AK) lesion reduction without the local irritation of approved topical AK treatment … Continued

More >

CritiTech PES partner NanOlogy Adds Clinical Trial Sites for Phase 2 Clinical Trials of NanoPac® in Pancreatic Cancer and Pancreatic Mucinous Cysts

Preliminary Data from Both Trials Show NanoPac Well-Tolerated via Intratumoral and Intracystic Injection FORT WORTH/DALLAS, (August 8, 2018) — NanOlogy LLC, … Continued

More >

CritiTech PES partner NanOlogy™ Completes Dose Escalation Portion of Phase 2 Clinical Trial of NanoPac® for Treatment of Prostate Cancer

Intratumoral injection of three concentrations of NanoPac successfully completed across a total of 9 patients Highest concentration of NanoPac continues … Continued

More >

NanoPac® Inhalation Treatment of NSCLC in a Nude Rat Orthotopic Lung Cancer Model

Background: NanoPac® is patented submicron particle paclitaxel in stable powder form without coating or carrier agents. In a previous PK study, … Continued

More >

Targeted Delivery of Submicron Particle Cancer Chemotherapy: Helping Shift the Immunotherapy Paradigm

NanOlogy™, a clinical-stage pharmaceutical development company, was formed in 2015 to increase the effectiveness and safety of CT through targeted … Continued

More >

Pharmacokinetic Profile of Inhaled Submicron Particle Paclitaxel (NanoPac) in a Rodent Model

Inhaled chemotherapeutics may enhance pulmonary drug exposure to malignant lesions in the lung without substantially contributing to systemic toxicities. The … Continued

More >

Evaluation of Submicron Particle Docetaxel Directly Injected into Uro-Oncologic Xenografts

Suspensions of submicron particle taxanes (Figure 1) allow for direct administration of high, sustained levels of chemotherapeutics at the site … Continued

More >

CritiTech PES partner NanOlogy announces First Patient Enrolled in a Phase 1/2 Clinical Trial of NanoDoce® for Treatment of Bladder Cancer

NanOlogy may offer an alternative treatment option for patients with bladder cancer Investigational drug, NanoDoce, is injected locally into tumor … Continued

More >

CritiTech PES partner NanOlogy Named to BioSpace Top 20 Life Science Startups to Watch in 2019

BioSpace is proud to present its NextGen Bio “Class of 2019,” a list of 20 up-and-coming life science companies in North America that launched* … Continued

More >